Compare DuPont de Nemours Inc (DD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Pfizer Inc — how do they compare? DuPont de Nemours Inc trades at $131.49 (market cap $17.89B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 8.9× DuPont de Nemours Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Pfizer Inc for 158 Days on average.
| DD | PFE | |
|---|---|---|
Market Cap | $17.89B | $158.56B |
Volume | 816,409 | 44,138,282 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $29.02 |
52-Week Low | $92.49 | $23.67 |
Typical Hold Time | 89 Days | 158 Days |
Enterprise Value | $19.28B | $210.06B |
Dividend Yield | 1.81% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with a neutral technical signal and mixed fundamentals. Recent earnings have consistently beaten estimates, but 2025 saw a net loss of $779 million on revenue of $6.85 billion. The company maintains innovation with new product launches like the Sugar Separation Advisor and Tyvek with Renewable Attribution, while facing headwinds from legal settlements and uneven demand.
The outlook is cautious; analyst consensus is bullish with a 58.54% buy rating but a price target of $95.00 below the current price. Key opportunities include margin expansion in growth markets, while risks involve PFAS litigation costs, volatile cash flows, and execution challenges in a competitive landscape.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
